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Poster Session II S313and 96 standard. ForHLA, there were 45HLA 10/10, 14HLA 9/10,
1 HLA 8/10 and for UCB 14 HLA 4/6 and 3 HLA 5/6. After a me-
dian follow-up of 25 months (0.2- 234), the median OS was 78
months (51–133) for transplanted patients with SD (3years OS:
68%), it was 33 months (27–47) for transplanted patients with UD
(3years OS:44%), 21 months (15–37) for not transplanted patients
with available SD or UD (3years OS:34%) and it was 31 months
(23-221) for patients with ND (3years OS:45%). Median EFS for
the same groups was 38 months (23–133), 24 months (17–36), 15
months (11-24) and 23 months (14–48) respectively. In multivariate
analysis, 3 significant factors affected OS: disease status (\CR) HR
5 2.8 [1.5-5.3] p\0.001; long interval diagnosis-registration HR5
2 [1.2-3.6] p 5 0.001 and conditioning (standard) HR 5 0.27 [0.1-
0.8] p5 0.02. The interval diagnosis-registration appeared as major
factor affecting survival in UD allo-HSCT settings.
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LONG TERM OUTCOMES OF ALLOGENEIC TRANSPLANT USING NON-RA-
DIATION BASED PREPARATIVE REGIMENS FOR ACUTE LYMPHOBLASTIC
LEUKEMIA
Al-Khabori, M., Al-Rawas, A., Al-Kindi, S., Al-Huneini, M., Al-
Farsi, K., Al Mandhari, I., Al-Mahrizi, R., Al-Zadjali, S.,
Dennison, D. Sultan Qaboos University Hospital, Al-Khoud, Muscat,
Oman
The role of total body irradiation (TBI) in the preparative regimen
before allogeneic stem cell transplantation has been debated. It is as-
sociated with higher rates of toxicity. Herein, we report the long
term outcomes of 26 consecutive pediatric and adult patients trans-
planted for acute lymphoblastic leukemia (ALL) in our center with
non-TBI based preparative regimens from February 1996 to June
2010. All records were retrospectively reviewed. The median age
was 15 years (y); range 4-31, with 18 males and 8 females. Thirteen
were in first complete remission (CR1), 12 in CR2 and 1 patient with
progressive disease at the time of transplant. All preparative regimens
comprised of busulfan combined withmelphalan in 3, cyclophospha-
mide in 14 and fludarabine in 9 patients. The source of the graft was
bone marrow in 14 and peripherally collected stem cells in 12 pa-
tients. The median follow up was 54 and 83 months (mos) for all
and alive patients respectively. During the study follow up, there
were 9 relapses and 9 deaths (8 relapse related). The median overall
survival (OS) was 18 mos (95% confidence interval [CI]: 4-21) with
5-y probability of 63% (95% CI: 40-79%). The median disease free
survival (DFS) was 10.4 mos (95% CI: 5-19) with 5-y probability of
61% (95% CI: 39-78%). The 5-y cumulative incidence of relapse
was 39% (95% CI: 19-58%) for all group, 13% (95% CI: 0.5-
44%) for patients aged upto 12 y and 53% (95%CI: 25-75%) for pa-
tients over 12 y of age. Thirty-three percent of patients (95%CI: 13-
54%) had acute graft versus host disease (aGvHD) grade 2 while
none had grade 3-4. Nineteen percent (95% CI: 1-37%) had exten-
sive chronic GvHD while only one had limited cGvHD. In the mul-
tivariable Cox model of OS using age (continuous variable) and
disease status at transplant (CR2 versus CR1), both factors were sta-
tistically significant. The hazard ratio (HR) of age and disease status
were 1.18 (95% CI: 1.03-1.35) and 10.90 (95% CI: 1.05-112.30) re-
spectively. In conclusion, non-TBI based preparative regimen in
children with ALL is a reasonable alternative with excellent results.
The age and disease status at transplantation have major impact on
survival of those patients. Further larger study is needed to validate
these results.
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DISEASE IN PATIENT UNDERGOING ALLOGENEIC STEM CELL TRANS-
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NMA conditioning with TLI/ATG (TA) has shown remarkably
low rates of acute graft-versus-host disease (GVHD) and non-re-
lapse mortality (NRM). Randomized comparisons of TA withmore intense conditioning regimens have not been performed. We
report here a retrospective comparison of transplant outcome fol-
lowing NMA with TA or reduced ‘‘toxicity’’ conditioning with flu-
darabine, busulfan and ATG (FBA), in cohort of patients deemed
not suitable for conventional myeloablative conditioning regimens.
The study group consists of 48 consecutive patients who under-
went ASCT after conditioning with FBA (n 5 37) or TA (n 5 11)
because of advanced age or presence of co-morbidities. FBA regimen
consisted of fludarabine 40mg/m2/day and busulfan 130mg/m2/day
intravenously x4 doses starting day -6 and ATG 2mg/kg/day for 3
days, starting day -3. TA group received ATG 1.5mg/kg/day for 5
days and TLI dose of 800 cGy starting day -11.
Baseline characteristics are in table 1.
Table 1. Patient Characteristics
Variables FBA (n537) TA (n511) p - valueSex : n (%) 0.74
Men 21 (57) 7 (64)
Women 16 (43) 4 (36)
Age: median (range) 53 (17-65) 58 (38-70) 0.20
Diagnosis: n (%) 0.01
Acute Leukemia/MDS 24 (65) 2 (18)
Non-Hodgkin Lymphoma 8 (22) 8 (73)
Chronic Leukemia 3 (8) 1 (9)
Plasma Cell Disorder 2 (5) 0 (0)
Remission Status: n (%) 0.09
Chemo-sensitive 28 (76) 11 (100)
Chemo-refractory 9 (24) 0 (0)
Risk group: n (%) 0.25
Standard risk 12 (32) 1 (9)
High risk 25 (68) 10 (91)
Prior autologous transplant: n
(%)5 (13) 1 (9) 1.00Donor type: n (%) 0.26
Sibling 9 (24) 5 (45)
Unrelated 28 (76) 6 (55)
HLA mismatch: n (%) 7 (19) 1 (9) 0.66
CD 34+ dose: median (range) [x
10*6/Kg body weight]7.2 (4-12.8) 5.1 (2.6-9) 0.03The median follow up of surviving patients is 1 year. The rate of
grade II-IV acute GVHD in the FBA and TA groups was 45.9%(n
5 17) and 36.3% (n 5 4) respectively (p 5 0.73). Rate of Grade
III-IV acute GVHD in the two groups was 8% (n 5 3) and 36.3%
(n5 4) respectively (p5 0.02). The rate of chronicGVHD in similar
order was 37.8% and 36.8% (p5 1.0). Post transplant rates of proven
bacterial, fungal and BK virus infections and CMV reactivation were
similar between the two groups (p. 0.05). The cumulative incidence
of disease relapse at 2years for FBA and TA groups was 46% and
10% respectively (p 5 0.1). non-relapse mortality (NRM) for the
FBA and TA cohorts at day 100 (2% vs.0%) and 2 years (31%
vs.30%) was not significantly different (p 5 0.3). Compared to
FBA group, TA groups showed trends towards improved 2 year
OS (40% vs.60%; p 5 0.07) and significantly better 2year progres-
sion free survival (36% vs.60%; p 5 0.036).
Acknowledging the limitation of our study (including small sam-
ple size, retrospective nature, higher proportion of chemosensitive/
low-risk patients in TA group), it is worth noting that NRM rates
with TA are surprisingly identical to an ablative FBA conditioning.
Rates of grade III-IV acute GVHD are also significanlty higher de-
spite small patient numbers. The difference is PFS is likely due to
low relapse rates in a standard-risk patient population. Our data
highlight the need for prospective studies to define optimal
conditioning regimens.
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